Skip to main content
. 2018 Jan 19;103(5):840–848. doi: 10.3324/haematol.2017.180554

Figure 5.

Figure 5.

Kaplan-Meier estimate of progression-free survival in 32 evaluable patients with Hodgkin lymphoma receiving ruxolitinib.